دورية أكاديمية
Proteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discovery
| العنوان: | Proteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discovery |
|---|---|
| المؤلفون: | Bing Bai, David Vanderwall, Yuxin Li, Xusheng Wang, Suresh Poudel, Hong Wang, Kaushik Kumar Dey, Ping-Chung Chen, Ka Yang, Junmin Peng |
| المصدر: | Molecular Neurodegeneration, Vol 16, Iss 1, Pp 1-16 (2021) |
| بيانات النشر: | BMC, 2021. |
| سنة النشر: | 2021 |
| المجموعة: | LCC:Neurology. Diseases of the nervous system LCC:Geriatrics |
| مصطلحات موضوعية: | Alzheimer’s disease, Pathogenesis, Biomarker, Proteomics, Proteome, PTM, Neurology. Diseases of the nervous system, RC346-429, Geriatrics, RC952-954.6 |
| الوصف: | Abstract Mass spectrometry-based proteomics empowers deep profiling of proteome and protein posttranslational modifications (PTMs) in Alzheimer’s disease (AD). Here we review the advances and limitations in historic and recent AD proteomic research. Complementary to genetic mapping, proteomic studies not only validate canonical amyloid and tau pathways, but also uncover novel components in broad protein networks, such as RNA splicing, development, immunity, membrane transport, lipid metabolism, synaptic function, and mitochondrial activity. Meta-analysis of seven deep datasets reveals 2,698 differentially expressed (DE) proteins in the landscape of AD brain proteome (n = 12,017 proteins/genes), covering 35 reported AD genes and risk loci. The DE proteins contain cellular markers enriched in neurons, microglia, astrocytes, oligodendrocytes, and epithelial cells, supporting the involvement of diverse cell types in AD pathology. We discuss the hypothesized protective or detrimental roles of selected DE proteins, emphasizing top proteins in “amyloidome” (all biomolecules in amyloid plaques) and disease progression. Comprehensive PTM analysis represents another layer of molecular events in AD. In particular, tau PTMs are correlated with disease stages and indicate the heterogeneity of individual AD patients. Moreover, the unprecedented proteomic coverage of biofluids, such as cerebrospinal fluid and serum, procures novel putative AD biomarkers through meta-analysis. Thus, proteomics-driven systems biology presents a new frontier to link genotype, proteotype, and phenotype, accelerating the development of improved AD models and treatment strategies. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1750-1326 |
| Relation: | https://doaj.org/toc/1750-1326 |
| DOI: | 10.1186/s13024-021-00474-z |
| URL الوصول: | https://doaj.org/article/d98af69a4ec9457ab6934693ca6ed550 |
| رقم الأكسشن: | edsdoj.98af69a4ec9457ab6934693ca6ed550 |
| قاعدة البيانات: | Directory of Open Access Journals |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 17501326 |
|---|---|
| DOI: | 10.1186/s13024-021-00474-z |